drugset / Trial / NCT01998347

Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

NCT01998347 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

There are no standard chemotherapy regimens for metastatic esophageal cancer. Cisplatin plus 5-fluorouracil is widely used as first-line treatment with a response rate ranged from 30% to 40%. Combination of paclitaxel and cisplatin has been investigated in small size clinical trial, producing promising outcome.Liposome capsuled paclitaxel has been proved to be as effective as paclitaxel.The usefulness of the the regimen of paclitaxel liposome with cisplatin is evaluated by median survival time, progression free survival,and response rate.

Timeline

Start
2013-11
Primary completion
2017-12
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “slow enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 37.5 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Comparator fluorouracil Small molecule 200 mg/m2 Intravenous

Indications